Osaka, Japan

The Green Cross Corporation


USPTO Granted Patents = 264

% Expired Patents = 3.8



Trademarks = 2

Forward Citations = 2,991

Loading Chart...
Loading Chart...

559 inventors (with patents filed for the assignee):

goldMedal Kazumasa Yokoyama (72 out of 80 patents)

silverMedal Tadakazu Suyama (47 out of 47 patents)

bronzeMedal Chikara Fukaya (33 out of 34 patents)

4.  Satoshi Funakoshi (25 out of 25 patents)

5.  Taizo Ono (24 out of 24 patents)

6.  Takao Ohmura (21 out of 24 patents)

7.  Yahiro Uemura (20 out of 25 patents)

8.  Yoshio Arakawa (20 out of 20 patents)

9.  Yoshihisa Inoue (18 out of 18 patents)

10.  Yoshio Tsuda (18 out of 18 patents)

11.  Hee Jeong Seo (14 out of 25 patents)

12.  Youichiro Naito (14 out of 15 patents)

13.  Suk Ho Lee (13 out of 31 patents)

14.  Min Ju Kim (13 out of 20 patents)

15.  Masahiro Watanabe (13 out of 16 patents)


Core Competencies:
Bispecific Antibody
Cancer Treatment
SGLT2 Inhibitors
Anti-CD3 Antibody
Pharmaceutical Composition
Epidermal Growth Factor Receptor
Recombinant Human Serum Albumin
Immunoglobulin Purification
Therapeutic Agent
Infusion Preparation
Antimicrobial Agent
Protein Purification

264 patents:

The Green Cross Corporation, headquartered in Osaka, Japan, specializes in the development and manufacturing of innovative antibody therapeutics. The company focuses on advanced treatments for cancer, leveraging technologies such as bispecific antibodies and SGLT2 inhibitors. Their expertise extends to pharmaceutical compositions involving anti-CD3 antibodies and epidermal growth factor receptors, as well as the purification of immunoglobulins. Green Cross is committed to enhancing patient outcomes through cutting-edge biopharmaceutical solutions.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

The Green Cross Corporation
264 Patents

#66 in Osaka

#580 in Japan

#3,314 in the World

Osaka, JP
Osaka, Japan
Forward Citations = 2,991

559 inventors:

Please report any incorrect information to [email protected]
Loading…